Network Bio launched with $50 million in financing and a collaboration valued at $30 million with Nvidia to develop a cell-free RNA (cfRNA) foundation model. The startup plans to train models using large-scale tissue, blood, molecular, and longitudinal clinical datasets sourced through partnerships with academic medical centers including Mass General Brigham, the University of Pennsylvania, and the University of Colorado Anschutz. As part of the collaboration, Nvidia and Network Bio will use the Nexus self-supervised transformer approach to build a population-scale cfRNA foundation model and develop methods to convert biobank access into model-ready datasets. The companies said the platform is intended to support disease detection, biomarker discovery, and drug development. Investors in Network Bio include Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund, and JSL Health Capital, alongside other AI and life science funds.